OneMedNet Corp (ONMD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Health Information Services) last closed at $0.60. The rating moved from Overbought to Oversold on August 18, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$0.60
• Last changeMoved from Overbought to Oversold on August 18, 2026
• SectorHealthcare
• IndustryHealth Information Services

See all oversold Healthcare stocks →

AI analysis

OneMedNet is a highly speculative, low‑liquidity microcap with limited public financial disclosure and no clear recent corporate milestones in the provided data. Sector dynamics (diagnostics demand, CDMO tailwinds, AI analytics in payers) could provide upside if the company has relevant assets or secures partnerships, but the absence of filings, thin trading, and likely capital needs raise near-term downside and dilution risk. Given the high information asymmetry, short-term moves may be driven more by sentiment and liquidity than fundamentals; monitoring for filings, financing announcements, or material commercial agreements is essential to reassess outlook.

Key factors

• Very limited public financial disclosure and no recent EDGAR filing visibility, increasing information asymmetry
• Microcap equity with low liquidity and elevated intraday/overnight volatility
• No material recent corporate news or clear commercial milestones in the provided dataset
• Sector-level tailwinds (diagnostics demand, biologics/CDMO interest, AI-driven payer strategies) could create indirect opportunities if OneMedNet has relevant assets or partnerships
• Macro risk-on tone in US equities may modestly support small healthcare names in the near term
• Potential for binary outcomes (partnerships, financing, regulatory events) that would materially reprice the equity

Risks

• High information risk due to lack of up-to-date financial reports and public disclosures
• Severe liquidity risk resulting in wide bid/ask spreads and price gaps on low-volume trades
• Financing and dilution risk if the company needs capital to fund operations or R&D
• Execution risk: failure to commercialize products, sign partners, or reach revenue inflection points
• Regulatory and clinical development risk if the business depends on approvals or healthcare coverage decisions
• Competitive pressure from larger, better-capitalized healthcare and diagnostics firms

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.